Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Säkerhets- och tolerabilitetsstudie av ST-503 för småfiberneuropati-associerad eldfast smärta

30 oktober 2026 uppdaterad av: Sangamo Therapeutics

En multicenterfas 1 dubbelblind, randomiserad, skamkontrollerad dosökningsstudie för att bestämma säkerhet och tolerabilitet för enstaka dosintratekal ST-503-genterapi för eldfast smärta på grund av idiopatisk liten fiberneuropati (ISFN)

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

ST-503 is intended to deliver a modified copy of the gene which will ideally repress Nav1.7 tissue-related pain signals reaching the brain, which should reduce the refractory pain due to small fiber neuropathy (SFN).

Studieöversikt

Status

Upphängd

Detaljerad beskrivning

This research is being done to study a possible treatment for refractory pain due to small fiber neuropathy (SFN).

Small fiber neuropathy happens when something damages small nerve fibers in your skin, causing symptoms like painful tingling or burning sensations in your hands and feet. Pain originating in the nerves outside of the brain and spinal cord is defined by doctors as neuropathic pain. Scientists have discovered that certain proteins in our bodies called sodium channels are important for communicating pain signals in nerves, specifically, Nav1.7, Nav1.8 and Nav1.9. This first-in-human study will test the use of a type of experimental treatment called "gene therapy." The primary goal is to determine if it is safe and well tolerated. The second goal is to determine if it reduces the level of refractory pain due to SFN disease. The gene will be delivered into your cells using a special delivery tool called a vector.

Studietyp

Interventionell

Inskrivning (Beräknad)

27

Fas

  • Fas 2
  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Scottsdale, Arizona, Förenta staterna, 85260
        • HonorHealth
    • Arkansas
      • Little Rock, Arkansas, Förenta staterna, 72205
        • University of Arkansas for Medical Sciences
    • California
      • La Jolla, California, Förenta staterna, 92093
        • The University of California, San Diego
    • Maryland
      • Baltimore, Maryland, Förenta staterna, 21218
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Förenta staterna, 02114
        • Massachusetts General Hospital
    • New Hampshire
      • Lebanon, New Hampshire, Förenta staterna, 03766
        • Dartmouth Hitchcock Medical Center
    • New York
      • New York, New York, Förenta staterna, 10027
        • Columbia University Irving Medical Center (CUIMC) and New York-Presbyterian Hospital (NYPH)
    • North Carolina
      • Chapel Hill, North Carolina, Förenta staterna, 27514
        • University of North Carolina Medical Center
    • Tennessee
      • Nashville, Tennessee, Förenta staterna, 37235
        • Vanderbilt University
    • Utah
      • Salt Lake City, Utah, Förenta staterna, 84112
        • University of Utah
    • Virginia
      • Richmond, Virginia, Förenta staterna, 23284
        • Virginia Commonwealth University

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria

  1. Diagnostic characterization of Small Fiber Neuropathy (SFN) according to the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities and Networks (ACTTION) criteria.
  2. Medical record documentation that pain is refractory to 2 of 3 categories of first line medical therapy for at ≥ 6 months prior to screening.
  3. Serum sample negative for pre-existing anti-AAV9 antibodies determined by assay detection limit

Exclusion Criteria

  1. Drug- and alcohol-related:

    1. Persons using opioid analgesics for under 3 months or persons who are not on a stable dose of opioids; if on a stable dose, the dose may decrease over the course of the study but should not be increased.
    2. History of known alcohol abuse, opioid analgesic abuse, or illicit drug abuse within 2 years of Screening.
    3. Positive urine test for drugs of abuse (including opiates, benzodiazepines, amphetamines, cocaine, barbiturates, and phencyclidine) without prescription and investigator approval, at Screening and Day -1.
    4. Use of cannabinoids is not permitted.
  2. Persons with Fabry's disease, with erythromelalgia, with peripheral neuropathies due to alcohol or drug toxicity, or with diagnosed channelopathies

  3. Procedure-related:

    1. Contraindications to LP, general anesthesia or sedation
    2. Any medical disorders that, in the opinion of the Investigator, could interfere with LP including but not limited to evidence for a pressure gradient between supratentorial and infratentorial compartments, Arnold-Chiari malformation, bleeding diathesis, clinically significant coagulopathy, thrombocytopenia, increased intracranial pressure, or spine disease or past surgical procedures involving the spine
  4. Infectious disease-related:

    1. Active viral infection or bacterial
    2. A severe infection (e.g., pneumonia, septicemia, central nervous system infections [e.g., meningitis, encephalitis]) within 12 weeks prior to Screening
  5. Hepatic disease- and hepatotoxic medication-related:

    1. Presence of clinically relevant liver disease
    2. Hepatic dysfunction as indicated by one or more of the following: i. Albumin ≤ 3.5 g/dL ii. Total bilirubin > 1.5 x ULN and direct bilirubin ≥0.5 mg/dL iii. Alkaline phosphatase (ALP) > 2 x ULN iv. Alanine transaminase (ALT) or aspartate transaminase (AST) > 1.5 x ULN
    3. Hepatotoxic medications should be avoided during the study period including acetaminophen exceeding 4 gm/day unless essential to patient's treatment, approved by investigator, and hepatic dysfunction is not identified
    4. Hepatotoxic supplement use during the study period
  6. Cancer-related:

    a. History of cancer, including B-cell cancers, within 5 years of Screening

    i. Exceptions to this exclusion are fully excised non-melanoma skin cancers, non-metastatic prostate cancer, and fully treated ductal carcinoma in situ of the breast, provided subject has been stable for at least 6 months

    b. Previous autologous or allogeneic bone marrow transplant, peripheral stem cell transplant or solid organ transplantation

  7. Previously received gene or cellular therapy

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Sham Comparator: Skamkontrollerad studie

Sham Procedure

Experimentell: Utredningsagent

Genomic Medicine

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Incidence and severity of treatment emergent adverse events (TEAEs)
Tidsram: 12 weeks

To assess safety and tolerability of ST-503 over a 12-week post-dosing observation period.

12 weeks

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Percentage of subjects with pain intensity reduction from baseline at Week 12
Tidsram: 12 weeks
  • 30% in the weekly average of daily pain intensity measurements performed using the PI-NRS

  • 50% in the weekly average of daily pain intensity measurements performed using the PI-NRS

    • Dose of rescue medication use
    • Frequency of rescue medication use
12 weeks
Percentage of subjects at Week 12
Tidsram: 12 weeks
  • Categorized as improved on the patient global impression of change (PGIC) assessment
  • With a ≥ 1-point improvement in suicidal ideation in Columbia Suicide Severity Rating Scale (C-SSRS) responses
12 weeks
Columbia Suicide Severity Rating Scale (CSSRS) Rating
Tidsram: 12 weeks

With a ≥ 1-point decline in suicidal ideation in Columbia Suicide Severity Rating Scale (CSSRS) responses

12 weeks
Overall Pain Intensity Numerical Rating Scale (PI-NRS) score
Tidsram: 12 Weeks

Participants will rate their pain intensity using an 11-point Numerical Rating Scale (0=no pain and 10=worst possible pain) and record their score in an electronic diary.

12 Weeks
Short Form McGill Pain Questionnaire-2 (SF-MQ-2)
Tidsram: 12 Weeks

This pain scale was developed to evaluate chronic neuropathic and non-neuropathic pain in adults. It consists of 22 descriptors of pain in 4 parts (continuous, intermittent, neuropathic, and affective pain types) to be rated from 0-10 with 0 indicating no pain and 10 the worst pain ever during the past week.

12 Weeks
Daily Sleep Interference Score (DSIS)
Tidsram: 12 Weeks

DSIS is assessed on an 11-point NRS, which ranges from 0 (none) to 10 (severe).

12 Weeks
Hospital Anxiety and Depression Scale (HADS)
Tidsram: 12 Weeks

HADS is a screening tool for anxiety and depression in non-psychiatric clinical populations consisting of 14 items (seven each for anxiety and depression). Higher scores correlate with worse symptoms.

12 Weeks
Rasch-Transformed 13-item SFN Symptoms Inventory Questionnaire
Tidsram: 12 Weeks

The 13-item SFN-SIQ evaluates changes in physiological functions such as sweating patterns and incontinence using a four-point Likert scale (0 = never present, 1 = sometimes, 2 = often, and 3 = always present) to get a sum of the grading scores attributed to each of the 13 items with a 0 to 39 range. Higher scores correlate with worse symptoms.

12 Weeks
SFN-specific Rasch-built Overall Disability Scale (SFN-RODS)
Tidsram: 12 Weeks

The 32-item SFN-RODS is a disease-specific interval measure suitable to detect activity limitations and participation restrictions in patients with SFN. The scale ranges from 0 to 64 with higher numbers indicating worse disability.

12 Weeks
36-Item Short Form Health Survey (SF-36) domains and summary scores
Tidsram: 12 Weeks

This measures quality of life measures such as physical functioning, emotional well-being, energy levels, and social functioning. The range is from 0-100 with higher scores being associated with a better perceived quality of life.

12 Weeks
Pain Catastrophizing Questionnaire (PCS)
Tidsram: 12 Weeks

PCS has 13 questions related to rumination, magnification and helplessness with values ranging 0 to 4 for a total possible score of 52. The higher the score the more pain catastrophizing is present.

12 Weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Studierektor: Medical Monitor, Sangamo Therapeutics Inc.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

4 december 2025

Primärt slutförande (Beräknad)

1 juli 2027

Avslutad studie (Beräknad)

1 juli 2028

Studieregistreringsdatum

Först inskickad

30 april 2025

Först inskickad som uppfyllde QC-kriterierna

12 maj 2025

Första postat (Faktisk)

20 maj 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

3 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

30 oktober 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera